Shield Therapeutics PLC Appointment of Non-Executive Director (8012V)

TIDMSTX

RNS Number : 8012V

Shield Therapeutics PLC

26 July 2018

Shield Therapeutics plc

("Shield" or the "Company")

Appointment of Non-Executive Director

London, UK, 26 July 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Hans-Peter Hasler as a Non-Executive Director of the Company with immediate effect.

Mr Hasler is the founder and CEO of Vicarius Pharma and an Advisor to SBTech Global Advisory. His prior experience includes roles as COO, Elan Corporation, and several senior positions at Biogen, Inc., including Chief Operations Officer. Previously, Mr. Hasler was at Wyeth Pharmaceuticals as Senior Vice President, Chief Marketing Officer and Managing Director of Wyeth Group Germany, Wyeth-Lederle Switzerland, Austria and CEE. Mr Hasler is Chairman of HBM Healthcare Investments AG in Switzerland, Chairman of MIAC Medical Imaging Analysis Center of the University Hospital of Basel, and a Director of the Board of Minerva Neuroscience Inc., Boston.

Carl Sterritt, CEO of Shield Therapeutics, said: "On behalf of the Board I'd like to welcome Hans-Peter to Shield and trust his broad experience of commercial operations and negotiations in pharmaceutical transactions will be a great asset to the Company in the coming months and beyond."

Regulatory Disclosures

The following disclosures are required regarding Hans-Peter's appointment pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name and age: Hans-Peter Hasler, aged 62

Hans-Peter holds or has held the following directorships in the five years preceding his appointment at the Company:

 
 Current Directorships          Former Directorships 
 HBM Healthcare Investment AG   Acino Holding AG 
 MIAC AG                        AOP Orphan Pharmaceuticals 
 Minerva Neuroscience Inc.      Celltrion Inc. 
 Vicarius Pharma AG             Dr Reddy's Labs 
                                Ferring Holding S.A. 
                                Pantheon N.V. 
                                Rigi Healthcare AG 
 

No further disclosure is required under AIM Rule 17 and paragraph (g) to Schedule Two of the AIM Rules with respect to Hans-Peter Hasler.

- Ends -

For further information please contact:

Shield Therapeutics plc [phone]

Carl Sterritt, Chief Executive Officer

Nominated Advisor and Joint Broker [phone]

Liberum Capital Limited

Christopher Britton/Steve Pearce

Joint Broker [phone]

Peel Hunt LLP

James Steel/ Dr Christopher Golden

Financial PR Advisor [phone]

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOADBGDRRGDBGIU

(END) Dow Jones Newswires

July 26, 2018 02:02 ET (06:02 GMT)